PRTA stock sentiment todayProthena Corporation PLC

A high-risk, high-reward Alzheimer's play with strong institutional backing offset by recent insider selling and clinical binary risk.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for PRTA. Not financial advice.

Market sentiment is currently tug-of-war; significant 10% owner accumulation suggests long-term conviction, while a recent CSO sale and a 3.6% daily drop indicate short-term volatility. The narrative is driven by its 6-month momentum versus current valuation debates.

• ·Significant 10% owner buying activity
• ·Insider selling by Chief Strategy Officer
• ·Inclusion in value-investor comparison discussions
• ·Speculation ahead of clinical data presentations

Prothena maintains a robust cash position (approx. $600M+) relative to its burn rate, providing a multi-year runway. While currently pre-revenue/loss-making, its partnership-heavy model with BMS and Roche mitigates some financial strain.

• ·Cash runway into 2027
• ·High R&D expenditure to revenue ratio
• ·Negative EPS typical for clinical-stage biotech
• ·Strong institutional ownership base

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Strong conviction — insiders and patient capital are backing this.

• ·Insiders bought a net $9.0M on the open market in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Clinical failure of lead candidate PRX012 (Alzheimer's)
• ·Regulatory hurdles with the FDA for amyloid-targeting therapies
• ·High stock price volatility linked to sector-wide biotech rotations
• ·Dependency on partner milestones (Roche/BMS) for liquidity

How direct competitors stack up against PRTA right now.

• NEUTRAL
  BIIBBiogen Inc.

  COLDER — despite having approved products, Biogen faces stagnant legacy revenue compared to PRTA's high-ceiling pipeline upside.

  See full analysis →
• COLD
  SNTGSenstar Technologies

  COLDER — lacking the high-tier pharmaceutical partnerships and specialized amyloidosis focus that PRTA commands.

  See full analysis →
• HOT
  ACADACADIA Pharmaceuticals

  HOTTER — offers a more de-risked profile with established commercial revenue from NUPLAZID while maintaining a CNS pipeline.

  See full analysis →

Consensus average of 4 analysts · median 30.00

Source: StockAnalysis.com · updated 2026-08-07

• Yahoo! Finance Canada
  CDNL,CC,ANGX,NTHI,AMRC,PRTS,LIEN,AGMB,RGCO,DFH,PRTA,SELF,TISI,AIAI,EQPT,REFI,BRID,RVSB,AFCG,SRTS,BGDE,WVVI,FUL,GME | Stock Prices | Quote Comparison - Yahoo Finance
• Stock Titan
  A ten-percent owner buys Prothena (PRTA) shares at average prices of $8.1852 and $8.0705.
• CNN
  symbol__ Stock Quote Price and Forecast
• Quiver Quantitative
  Insider Sale: Chief Strategy Officer of $PRTA Sells 7,662 Shares
• Yahoo Finance
  PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?
• Gotrade
  Prothena Corporation plc (PRTA) Stock Price: Oct 29 Close $8.88